Daihan Pharmaceutical: Infusion Manufacturer with Improving ROE

Hoosik Min of Pine Investment Advisory presented his in-depth investment thesis on Daihan Pharmaceutical (KOSDAQ: 023910) at Asian Investing Summit 2018. Daihan is a manufacturer of infusions.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

First name:

Last name:

Email address:

City / state / country:

Company:

How did you hear about MOI Global? Select Member referral Staff This website Media / Internet Other

If referral, please provide member's name:

Which of the following applies most closely to you? Select Investment Firm - Head Investment Firm - Analyst or PM Institutional Allocator - Firm C-Level Executive Institutional Allocator - Firm Employee Family Office - Head or Co-Owner Family Office - Employee Non-Investment Firm - C-Level Executive Non-Investment Firm - Employee Other

How do you hope to add value to the community?

Leave this field empty if you're human:

About the instructor:

Hoosik (Michael) Min holds a B.A from Hankuk University of Foreign Studies and an M.B.A. in Finance from the University of Denver. Michael began his career in 1989 as an IT sector analyst at Coryo Securities, Tongyang Securities, Dongwon Securities, and Korea Investment & Securities. After 2007, he served as CIO in the Asset Management Department of Tempis Capital Management for three years and founded Pine Investment Advisory in 2010. He serves as chief investment officer.